prsync

Respiratory Syncytial Virus (RSV) Infections Pipeline Review 2017

Press Release   •   Jun 01, 2017 15:44 IST

Respiratory Syncytial Virus (RSV) Infections Pipeline Review H1 2017 report provides comprehensive information on the therapeutics under development for Respiratory Syncytial Virus (RSV) Infections, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. Additionally, the report provides an overview of key players involved in therapeutic development for Respiratory Syncytial Virus (RSV) Infections and features dormant and discontinued projects.

Inquire for Complete PDF Report @ http://www.reportsnreports.com/contacts/inquirybeforebuy.aspx?name=1020026

Description of Report:

Respiratory Syncytial Virus (RSV) Infections Pipeline Review H1 2017 report reviews therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase II, Phase I, Preclinical, Discovery and Unknown stages are 3, 1, 3, 1 and 3 respectively. Similarly, the Universities portfolio in Preclinical stages comprises 1 molecule, respectively.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive.

Respiratory Syncytial Virus (RSV) Infections Key Companies Analysed:

Abivax SA, Ablynx NV, ADMA Biologics Inc, Agilvax Inc, Amarillo Biosciences Inc, Anima Biotech Ltd, Aridis Pharmaceuticals LLC, Artificial Cell Technologies Inc, AstraZeneca Plc, Aviragen Therapeutics Inc, Bavarian Nordic A/S, Celltrion Inc, Curevac AG, DBV Technologies SA, Emergent BioSolutions Inc, Enanta Pharmaceuticals Inc, Evec Inc, F. Hoffmann-La Roche Ltd, Gene Techno Science Co Ltd, GenVec Inc, Gilead Sciences Inc, GlaxoSmithKline Plc, Globavir Biosciences Inc, Humabs BioMed SA, iBio Inc, Immunovaccine Inc, Immunwork Inc, Inovio Pharmaceuticals Inc, Johnson & Johnson, Karyopharm Therapeutics Inc, Kineta Inc, mAbxience SA, MedImmune LLC, Medivir AB, Merck & Co Inc, Mucosis BV, Mymetics Corp, NanoBio Corp, Navigen Inc, Novavax Inc, Phoenix Biotechnology Inc, Profectus BioSciences Inc, Pulmocide Ltd, Regeneron Pharmaceuticals Inc, ReViral Ltd, Romark Laboratories LC, Sanofi, Spring Bank Pharmaceuticals Inc, Takeda Pharmaceutical Company Ltd, TechnoVax Inc, Themis Bioscience GmbH, Vault Pharma Inc, Vaxart Inc, VBI Vaccines Inc, Virometix AG, Visterra Inc, VLP Biotech Inc.

Get Discount On Report @ http://www.reportsnreports.com/contacts/discount.aspx?name=1020026 . (This report is available at upto 25% Discount till June 02nd 2017.)

The report provides a snapshot of the global therapeutic landscape of Respiratory Syncytial Virus (RSV) Infections. The report reviews pipeline therapeutics for Respiratory Syncytial Virus (RSV) Infections by companies and universities/research institutes based on information derived from company and industry-specific sources. The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages. The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities. The report reviews key player’s involved Respiratory Syncytial Virus (RSV) Infections therapeutics and enlists all their major and minor projects. The report assesses Respiratory Syncytial Virus (RSV) Infections therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report summarizes all the dormant and discontinued pipeline projects. The report reviews latest news related to pipeline therapeutics for Respiratory Syncytial Virus (RSV) Infections advantage.

Major Table OF Content

  • Number of Products under Development for Respiratory Syncytial Virus (RSV) Infections, H1 2017
  • Number of Products under Development by Companies, H1 2017
  • Number of Products under Development by Universities/Institutes, H1 2017
  • Products under Development by Companies, H1 2017
  • Products under Development by Universities/Institutes, H1 2017
  • Number of Products by Stage and Target, H1 2017
  • Number of Products by Stage and Mechanism of Action, H1 2017
  • Number of Products by Stage and Route of Administration, H1 2017
  • Number of Products by Stage and Molecule Type, H1 2017
  • Respiratory Syncytial Virus (RSV) Infections - Pipeline by Aphios Corp, H1 2017
  • Respiratory Syncytial Virus (RSV) Infections - Pipeline by Cannabis Science Inc, H1 2017
  • Respiratory Syncytial Virus (RSV) Infections - Pipeline by CytRx Corp, H1 2017
  • Respiratory Syncytial Virus (RSV) Infections - Pipeline by LATITUDE Pharmaceuticals Inc, H1 2017
  • Respiratory Syncytial Virus (RSV) Infections - Pipeline by RedHill Biopharma Ltd, H1 2017
  • Respiratory Syncytial Virus (RSV) Infections - Pipeline by Tumorend LLC, H1 2017
  • Respiratory Syncytial Virus (RSV) Infections - Pipeline by VasGene Therapeutics Inc, H1 2017
  • Respiratory Syncytial Virus (RSV) Infections - Dormant Projects, H1 2017
  • Respiratory Syncytial Virus (RSV) Infections - Dormant Projects, H1 2017 (Contd..1), H1 2017
  • Respiratory Syncytial Virus (RSV) Infections - Discontinued Products, H1 2017

Direct Purchase This Report @: http://www.reportsnreports.com/purchase.aspx?name=1020026

Contact Us:

Ritesh Tiwari

2nd Floor, Metropole,

Bund Garden Road,

Pune – 411001,

India.

Tel: + 1 888 391 5441

E-mail: sales@reportsandreports.com

Reportnreports.com provides market research reports to industries, individuals and organizations with an objective of helping them in their decision making process. Our library of 500,000+ industry & country research reports covers 5000+ micro markets. This comprehensive collection of market research reports include market share analysis, industry analysis, information on products, countries, market size, trends, business research details and much more..